Efficacy of cisplatin in combination with paclitaxel for oral cancer and its effect on cellular immunity

Zhongyi Zhang, Yuanlong Zhao*
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

*For correspondence: Email: zhiyuantanyzqv@163.com

Abstract

Purpose: To study the efficacy of cisplatin in combination with paclitaxel in the treatment of oral cancer and its effect on cellular immunity.

Methods: A total of 100 patients with oral cancer, treated in the First Affiliated Hospital of Dalian Medical University from May 2018 to April 2020 were included and evenly allocated to study and control groups. The patients in the study group received cisplatin plus paclitaxel, while the patients in the control group received only cisplatin. The serum levels of T lymphocytes, interleukin (IL) -4, IL-2, and interferon gamma (IFN-γ) were determined.

Results: After treatment, the study group showed significantly higher levels of CD3+, CD4+ and CD4/CD8, but a lower CD8+ level (26.17 ± 2.14 μL) than those before treatment (p < 0.05). The control group was associated with higher post-treatment CD3+, CD4+, CD8+, and CD4/CD8 levels and lower CD8+ levels versus patients in the study group (p < 0.05). The study group showed higher levels of IL-2 and IFN-γ (246.77 ± 13.68 and 1194.62 ± 123.15 pg/mL, respectively), but lower IL-4 levels (392.48 ± 13.25 pg/mL) after treatment than before treatment. Control group was associated with higher post-treatment IL-2 and IFN-γ levels and lower IL-4 levels compared to patients in the study group (p < 0.05).

Conclusion: Cisplatin and paclitaxel combination offers a viable treatment alternative for oral cancer, as it enhances patients' immune function and disease prognosis, regulates inflammatory responses, and promotes patients' recovery. Further investigations in larger population settings are, however, recommended.

Keywords: Cisplatin chemotherapy, Paclitaxel, Oral cancer, Peripheral blood cells, Immune function

INTRODUCTION

Oral cancer is a common malignancy [1], including lip cancer, tongue cancer, jaw cancer, gum cancer, buccal mucosa cancer, etc. [2]. According to epidemiological statistics, there are nearly 300,000 new cases each year in recent years, and the pathogenesis is mainly related to biological and environmental factors [3,4]. The clinical symptoms of oral cancer mostly include pain, leukoplakia, and chronic oral ulcers [5,6]. Presently, surgical resection, radiotherapy, and chemotherapy are the mainstay of treatment for oral cancer [7]. However, the treatment outcome is suboptimal, and patients are still associated
with poor survival and high recurrence and metastasis rates [8].

Cisplatin is a broad-spectrum anti-tumor chemotherapeutic drug that has obtained promising results in treating solid tumors such as ovarian cancer, testicular cancer, and lung cancer [9]. It inhibits the synthesis of DNA and RNA in tumor cells to exert the anti-tumor function and plays a synergistic effect with 5-Florouracil (5-FU) [10]. Paclitaxel is a natural secondary metabolite obtained from *Taxus chinensis* and has good antitumor effects for breast cancer, ovarian cancer, and lung cancers [11]. In recent years, neoadjuvant chemotherapy with paclitaxel has achieved good clinical results [12,13]. This study was undertaken to investigate the efficacy of the combination of cisplatin and paclitaxel for oral cancer and its impact on cellular immunity.

**METHODS**

**Study population**

A total of 100 patients with oral cancer treated in the First Affiliated Hospital of Dalian Medical University between May 2018 and April 2020 were selected and assigned to the observation and control groups. The study was approved by the ethic committee of First Affiliated Hospital of Dalian Medical University (approval no. 20180230). The study was conducted in line with the protocol of Helsinki Declaration [14]. All the patients consented to participate in the study.

**Inclusion and exclusion criteria**

**Inclusion criteria**

Patients with oral squamous cell carcinoma, without allergies to the drugs used in this treatment, and with consciousness that allows normal communication were included.

**Exclusion criteria**

Patients with systemic diseases such as diabetes and hypertension, with autoimmune disease and use of immunosuppressive drugs, and who revoked their consent were excluded.

**Treatments**

Patients in the observation group received 100 mg/m² of cisplatin and 150 mg/m² of paclitaxel through an intravenous infusion 5 days starting on the first day of treatment, and repeated 30 days after first treatment. Approximately 2 mL of venous blood was collected from all participants for the determination of blood indices. All testing methods used were in line with the relevant laboratory diagnostic standards.

**Assessment of parameters/outcomes**

**Treatment efficacy**

If the symptoms and signs were significantly mitigated and the test indices were markedly improved after treatment, the treatment was considered markedly effective. After treatment, if the symptoms and signs were mitigated and the test indices were improved, the treatment was considered effective. If aggravations or no changes were observed in the symptoms and test indices after treatment, the treatment was considered ineffective.

**Peripheral venous blood test**

The blood samples were centrifuged, and the supernatant was collected for assays using the ELISA method. The determination of blood indices was performed as per the kit instructions.

**T-lymphocyte measurement**

Blood samples collected from each patient was divided into four portions of 100 μL in each group for assay. The first portion was added with FITC-labeled CD3 antibody and PE-labeled CD56 antibody, the second portion was added with FITC-labeled CD4 antibody and PE-labeled CD8 monoclonal antibody, the third portion was added with FITC-labeled CD4 antibody and PE-labeled INF-γ antibody, and the fourth portion was added with FITC-labeled CD4 antibody and PE-labeled IL-2 antibody, with the dose of each antibody sample being 10 μL. The specimens were then incubated for 1 h, added with red blood cell lysate, allowed to react for 10 min, and then centrifuged for 5 min, followed by the collection of the supernatant for assays using flow cytometry.

**Statistical analysis**

All data analyses were performed with SPSS 22.0 software. The count data (n (%)) are analyzed using the chi-square test. The measurement data (mean ± SD) were analyzed using t-test. A *p*-value less than 0.05 was set as the cut-off for statistical significance.
RESULTS

Baseline characteristics of patients

In the study group, there were 35 males and 15 females, 34 cases of clinical stage III, and 16 cases of clinical stage IV, and the participants were aged 51.23 ± 5.18 years. In the control group, there were 36 males and 14 females, 33 cases of clinical stage III, and 17 cases of clinical stage IV, and the participants were aged 51.08 ± 5.37 years. The patient characteristics between the two groups were comparable (p > 0.05) (Table 1).

Treatment effectiveness

After treatment, in the study group, there were 18 cases that were significantly effective, 25 cases were effective, and 7 cases were ineffective; while in the control group, there were 10 markedly effective cases, 20 cases were effective, and 20 cases were ineffective (Table 2).

Expression of T lymphocytes

After treatment, the study group showed higher levels of CD3+, CD4+, CD4/CD8 (66.86 ± 3.14, 39.69 ± 3.12, and 1.52 ± 0.13 μL) and a lower CD8+ level (26.17 ± 2.14 μL) than those before treatment (57.65 ± 2.68, 30.24 ± 3.62, 0.83 ± 0.14, and 39.51 ± 5.62 μL). The control group had a markedly higher post-treatment levels of CD3+, CD4+, CD8+, CD4/CD8 and lower CD8+ levels when compared with patients in the study group (p < 0.05; Table 3).

IL-2, IL-4, and INF-γ contents

The study group showed higher levels of IL-2 (246.77 ± 13.68 and 1194.62 ± 123.15 pg/mL) and lower IL-4 levels (392.48 ± 13.25 pg/mL) after treatment than before treatment (156.46 ± 10.33 884.23 ± 102.37, and 429.58 ± 17.35 pg/mL). The control group had higher post-treatment IL-2 and INF-γ contents and lower IL-4 contents versus patients in the study group (p < 0.05). (Table 4)

Table 1: Baseline feature (mean ± SD; n = 45)

| Group | Gender | Age (years) | Stage | Disease site |
|-------|--------|-------------|-------|--------------|
|       | Male/Female |           | III  | IV | Tongue | cheek | gums | floor of mouth |
| Study | 35/15 | 51.23±5.18 | 34   | 16 | 13 | 12 | 12 | 13 |
| Control | 36/14 | 51.08±5.37 | 33   | 17 | 12 | 14 | 11 | 13 |
| T/X²  | 0.049 | 0.315      | 0.045 | 0.086 |
| P-value | 0.826 | 0.893      | 0.832 | 0.776 |

Table 2: Effectiveness of treatment in the observation group (n = 50)

| Group | Markedly effective | Effective | Ineffective |
|-------|-------------------|-----------|-------------|
| Study | 18                | 25        | 7           |
| Control | 10               | 20        | 20          |
| X²    | 8.574             |           |             |
| P-value | <0.003           |           |             |

Table 3: Comparison of T lymphocyte expression (mean ± SD; n = 50)

| Group | CD3 (μL) | CD4 (μL) | CD8 (μL) | CD4/CD8 |
|-------|----------|----------|----------|---------|
| Study | Before treatment 57.65±2.68 | 30.24±3.62 | 39.51±5.62 | 0.83±0.14 |
|       | After treatment 66.86±3.14* | 39.69±3.12* | 26.17±2.14* | 1.52±0.13* |
| Control | Before treatment 57.82±2.89 | 32.42±2.59 | 37.48±5.99 | 1.35±0.16 |
|       | After treatment 68.96±3.53* | 42.69±3.14* | 29.47±2.64* | 1.92±0.43* |
| T     | 14.966 | 13.265 | 14.881 | 24.228 |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 |

Note: *Significant difference between pre- and post-treatment within the group (p < 0.05)

Table 4: Comparison of changes in IL-2, IL-4, and INF-γ levels between the two groups (mean ± SD, n = 50)

| Group | IL-2 (pg/mL) | IL-4 (pg/mL) | INF-γ (pg/mL) |
|-------|--------------|--------------|--------------|
| Study | Before treatment 156.46±10.33 | 429.58±17.35 | 884.23±102.37 |
|       | After treatment 246.77±13.68* | 392.48±13.25* | 1194.62±123.15* |
| Control | Before treatment 155.46±11.23 | 430.58±16.35* | 885.03±112.37 |
|       | After treatment 233.72±12.58* | 382.38±11.45* | 1124.32±113.15* |
| T     | 35.341 | 11.400 | 13.002 |
| P-value | <0.001 | <0.001 | <0.001 |

Note: * indicates a significant difference between pre- and post-treatment within the group (P < 0.05)
DISCUSSION

Oral cancer is clinically treated with surgical resection, supplemented with radiotherapy and chemotherapy [15], yet both have a high degree of recurrence and metastasis. Cisplatin is a clinical anticancer drug [16] with cell cycle non-specificity. It inhibits the synthesis of DNA and RNA to exert anti-tumor effects. Research has reported that cisplatin is effective in various solid tumors such as ovarian cancer and prostate cancer, testicular cancer, lung cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer and osteosarcoma [10]. Paclitaxel is a common drug in neoadjuvant chemotherapy with good antitumor activity [17].

In the present study, patients in the study group showed treatment effectiveness of 95.56 %, indicating that the combination of cisplatin and paclitaxel are effective for oral cancer. Moreover, the study group showed higher levels of CD3+, CD4+, CD4/CD8 after treatment and a lower CD8+ level than those before treatment suggesting that cisplatin and paclitaxel improve patient immunity and promote the recovery of patients. The results were consistent with the previous studies [18,19]. Additionally, the study group showed higher levels of IL-2 and INF-γ and lower IL-4 levels after treatment than before treatment and the differences in the three indices between the two groups were also statistically significant, suggesting alleviated inflammatory responses in the patients and enhanced secretion of cytokines after the use of cisplatin and paclitaxel. This outcome is similar to the previous research results that reported that inflammatory factors in peripheral blood increased significantly, and the immune function of peripheral blood cells was improved, resulting in diminished tumor volume [20].

CONCLUSION

The combination of cisplatin and paclitaxel offers a viable treatment alternative for oral cancer, as it enhances patients' immune function and improves disease prognosis, regulates their inflammatory responses, and promotes their recovery. However, further studies in larger population groups are recommended.

DECLARATIONS

Acknowledgements

None provided.

Funding

None provided.

Ethical approval

None provided.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol 2015; 8(9): 11884-11894.
2. Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther 2016; 12(2): 458-463.
3. Wong T, Wiesenfeld D. Oral Cancer. Aust Dent J 2018; 63 Suppl 1: S91-S99.
4. Dhanuthai K, Rojanawatirivej S, Thosapom W, Kintarak S, Subambhesaj A, Darling M, Kryshitalskyj E, Chiang CP, Shin Hl, Choi SY, et al. Oral cancer: A multicenter study. Med Oral Patol Oral Cir Bucal 2018; 23(1): e23-e29.
5. Sarode G, Maniyar N, Sarode SC, Jafer M, Patil S, Awan KH. Epidemiologic aspects of oral cancer. Dis Mon 2020; 66(12): 100988.
6. Sha J, Bai Y, Ngo HX, Okui T, Kanno T. Overview of evidence-based chemotherapy for oral cancer: focus on...
drug resistance related to the epithelial-mesenchymal transition. Biomolecules 2021; 11(6): 893.
7. Sadighi S, Keyhani A, Harirchi I, Garajei A, Aghili M, Kazemian A, Motiee Langroudi M, Zendehdel K, Nikpardo N. Neoadjuvant chemotherapy for locally advanced squamous carcinoma of oral cavity: a pilot study. Acta Med Iran 2015; 53(6): 380-386.
8. Vonk J, de Wit JG, Voskuil FJ, Witjes MJH. Improving oral cavity cancer diagnosis and treatment with fluorescence molecular imaging. Oral Dis 2021; 27(1): 21-26.
9. Sibuyi NRS, Moabelo KL, Fadaka AO, Meyer S, Onani MO, Madiehe AM, Meyer M. Multifunctional gold nanoparticles for improved diagnostic and therapeutic applications: a review. Nanoscale Res Lett 2021; 16(1): 174.
10. Kaya S, Wiesmann N, Goldschmitt J, Krüger M, Al-Nawas B, Heider J. Differences in the expression of caveolin-1 isoforms in cancer-associated and normal fibroblasts of patients with oral squamous cell carcinoma. Clin Oral Investig 2021; 25(10): 5823-5831.
11. Eckardt A, Wegener G, Karstens JH. Preoperative radiochemotherapy of advanced resectable cancer of the oral cavity with cisplatin vs paclitaxel/carboplatin: analysis of two multimodality treatment concepts. Mund Kiefer Gesichtschir 2006; 10(1): 30-36.
12. Warnakulasurya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MA, Kerr AR, Lodí G, Mello FW, Monteiro L, Ogden GR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO collaborating centre for oral cancer. Oral Dis 2021; 27(8): 1862-1880.
13. Pillai J, Chincholkar T, Dixit R, Pandey M. A systematic review of proteomic biomarkers in oral squamous cell cancer. World J Surg Oncol 2021; 19(1): 315.